Vanda Pharmaceuticals, Inc. (VNDA)

[Krakatoa_Dean]

I guess you were wrong jackson

[jackson227]

I just don't like seeing people buying into a stock that's up 1000% is all. I know that people that make that decision deserve what they get, but I just wanted to send out a couple warnings, that's all.

Nice job on the huge gains, and hope you took full profits.

I am a firm believer in take it when you can get it.

No offense intended, and you won't see me here anymore.

Just wanted to put in my 2 cents, which could be worth more or less than that, depending on who you ask.

GLTY too !

[||peace||}>

[elcheepo]

No sweat.. It just sounded like you were on the opposite side of the run.

I am fine.. and a little happier today.

Take care jackson.. glty

[jackson227]

Don't worry about it.

Just take my advice and take your profits, and hopefully for your sake you didn't buy in today.

: ^ )

[jackson227]

I've never shorted a share of anything in my life, but if you're long, then you just wait and see what happens.

This thing is going to drop like a ton of bricks.

GUARANTEED.

It's already down over $2 from the HOD, and that is only the beginning of the descent.

Thanks for playing.

[jackson227]

I'm not doing either, but I say how much it increased yesterday in A/H and know that it wouldn't hold.

This is going to continue to drop, so if you're up big, just take your profits and watch it fall.

[elcheepo]

Are you buying or selling?

[jackson227]

If you're long, don't be foolish.

Sell.

This will continue to go down, so be smart and take it when you can get it.

Let somebody else be the bagholder.

[jackson227]

Word on the street is wrong.

Crunch the numbers and do a proper valuation of the company's worth.

How many schizos do you think there are out there anyways?

[jackson227]

Cheers to those who sold and made bank. Too bad for those that are buying in right now.

[surf1944]

Surprising Approval for Vanda's Fanapt
05/07/09 - 10:24 AM EDT

Adam Feuerstein this B&^%$ was wrong again

Updated from 12:51 a.m. EDT

More on VNDA Latest News in Activist Investing Market Activity Johnson & Johnson| JNJ UPPfizer Incorporated| PFE UPHell froze over Wednesday night, right before a squadron of flying pigs took to the sky. These things must be true because the U.S. drug regulators also approved Vanda Pharmaceuticals'(VNDA Quote) treatment for schizophrenia.
The surprising -- some would say shocking -- approval of Vanda's drug Fanapt by the Food and Drug Administration sent shares of the company leaping more than 800% in Wednesday's after-hours trading session to just under $10 a share.

And no, that's not a typo. 800%. You read that correctly.

Wall Street had long ago left Fanapt for dead after the FDA rejected the drug in July 2008. The "not approvable" letter issued by the FDA at that time raised concerns about the efficacy of Fanapt and asked Vanda to conduct a new clinical trial and collect additional safety data.

Vanda didn't run a new clinical trial for Fanapt, choosing instead to resubmit the drug to the FDA last November with additional data from its existing clinical trials.

To say that investors considered this strategy to be long shot would be an understatement. Vanda's stock price fell well below $1, which valued the company at less than its cash on hand. Analysts either dropped coverage or downgraded the stock to a sell. The company was forced to lay off employees and cut back on other drug research programs.

On top of all that, activist hedge fund Tang Capital Partners bought up 3.96 million Vanda shares, or just under 15% of the company, and started a proxy fight for board seats in order to force Vanda to shut down and liquidate the remaining assets back to shareholders
http://www.thestreet.com/_yahoo/story/10497618/1/surprising-approval-for-vandas-fanapt.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

[elcheepo]

Word on the street... 30+ with this approval.

[SevenTenEleven]

What is going on here? Why the 10 fold increase in PPS?

[surf1944]

Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
On Thursday May 7, 2009, 9:00 am EDT

ROCKVILLE, Md., May 7 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA - News; "Vanda" or the "Company") announced today that Tang Capital Partners, LP ("TCP") has ended its proxy contest by withdrawing its nominations of director candidates for election to Vanda's Board of Directors and its stockholder proposal to liquidate the Company. TCP had previously notified the Company of its intention to solicit proxies for the election of two of its candidates to the Vanda Board at the Company's 2009 Annual Meeting and for its proposal that the Board take action to liquidate the Company.

Kevin Tang, the managing director of the general partner of TCP, notified Vanda of TCP's intention not to pursue a proxy contest on May 6, 2009 in an email to Vanda's Chief Executive Officer, Mihael H. Polymeropoulos, M.D. and Chairman of the Board, Argeris N. Karabelas, Ph.D. TCP's withdrawal of its nominations and stockholder proposal follows Vanda's announcement that the U.S. Food & Drug Administration had granted marketing approval of its product, Fanapt(TM) (iloperidone), for the acute treatment of adult patients with schizophrenia.

[Dog_Walker]

Everyone in this all I can say is I'm jealous! :)

[ernomad]

Test.

[powerbattles]

Congratulations longs! DAMP chasing all the way up MONSTER +824%

[RACKnRICKY]

i had may 6th circled on calander,but spaced it with ctic all day,

[BogeyMan]

Congrats to anyone holding shares! That is some very nice AH news!

[mkinhaw]

Surf is the connection to
TTNP still valid ?
its still listed on their website
MK

[foggdogg]

Congrats to all longs!!!

[Aiming4]

Congrats to all VNDA longs... maybe the FDA is loosening up a bit.

[surf1944]

http://www.mffais.com/vnda

the fund companies didn't see it coming

[creppie]

Congrats. Presumably, you held at least 10,000 shares.

[surf1944]

Vanda fights proposal to sellWashington Business Journal - by Vandana Sinha Staff Reporter

Mihael Polymeropoulos told Vanda employees to carry on, despite calls for the company to sell itself.
View Larger Related News
Still courting FDA, Vanda Pharmaceuticals waits again for approval
Amylin, Lilly, Alkermes submit FDA application for exenatide
Evogen seeks FDA emergency approval for swine flu test
Biotechs go without CFOs in midst of recession
Tang Capital makes bid for Northstar Neuroscience
Vanda Pharmaceuticals Inc. is opposing a recent shareholder proposal to replace two board members and for the Rockville company to sell itself.

Tang Capital Partners LP, which owns nearly 15 percent of Vanda’s shares, has said it plans to submit the names of its own two executives to replace two board members whose terms are set to expire this year, including Vanda Chief Executive Officer and founder Mihael Polymeropoulos and Chairman Argeris Karabelas. Tang, which has criticized Vanda’s plummeting market value, has also called for the company to shut down, sell off its parts and distribute the returns to fellow shareholders.

“The board is disappointed that Tang Capital has opted to conduct an election contest, particularly when the company is so close to receiving a response from the FDA regarding its lead compound, iloperidone,” said Brian Halak, a Vanda (NASDAQ: VNDA) board member. “Instead of working with us to maximize stockholder value, Tang Capital has chosen to create unnecessary costs and distractions for the company at this important time.”

Vanda is awaiting the Food and Drug Administration’s decision on iloperidone, its schizophrenia drug candidate, in May -- the second time the biotech finds itself at this point after getting rejected the first time last July. That sent the company’s stock price spiraling downward, and has led to layoffs that cut its staff in half, also affecting some executive team members. Vanda has also postponed its clinical and commercial activities until it hears FDA’s final word on iloperidone.

Vanda said those moves have slashed its spending considerably, making such a shift in board makeup unnecessary and more expensive. The company said it plans to remain in operation, a decision it said could only be counteracted now by a unanimous shareholder vote for liquidation.

“The company believes that, even in the absence of an approval by the FDA for iloperidone, there remains significant unrealized value in the company’s other compounds,” Vanda said in a statement. “Therefore, the company does not believe that liquidation is currently in the best interests of the company or its stockholders and intends to oppose TCP’s proposal to liquidate the company.”

Company officials said they are the latest victim of shareholder activism. “This will play out over the weeks and months to come, and I will be as transparent with you as possible,” Polymeropoulos wrote in a letter to employees Monday. “While this may be a distraction, I do not anticipate any interruption in our day-to-day business as a result of Tang Capital’s proposal.”

[sytofreak]

i bought a week and just sold for over 10 bux! I'm rich...well I have a lot more money than I did before

[mkinhaw]

Not anymore
lol
MK

[surf1944]

Tang Capital Partners' Proxy Statement for Vanda Pharmaceuticals Calls for Liquidation
again shows you you that big money is not always smart money
Tang Capital Partners has filed a preliminary proxy statement for the Vanda Pharmaceuticals (Nasdaq: VNDA) 2009 Annual Meeting of Stockholders urging stockholders to support Tang Capital Partners’ slate of two director nominees, Kevin C. Tang and Andrew D. Levin, M.D., Ph.D.

We’ve been following VNDA (see our post archive here) because it’s trading below its net cash value and Tang Capital Partners (TCP), has called for the company to “cease operations immediately, liquidate [VNDA]’s assets and distribute all remaining capital to the Stockholders.” The stock is up 16.7% since we initiated the position from $0.78 to close yesterday at $0.91, which gives the company a market capitalization of $24.3M. We estimate the net cash value to be around 75% higher at $42.6M or $1.60 per share.

The company is hemorrhaging cash, so the investment turns on TCP’s ability to get control and staunch the bleeding. If TCP cannot get onto the board quickly or at all, the company will continue to burn cash and the investment will be a dud. VNDA has a staggered board, so this will make TCP’s task difficult.

The Background and reasons for the solicitation in the preliminary proxy statement is set out below:


Tang Capital has engaged in discussions with the Company and the Board with regards to the strategic direction of the Company. We believe that in order to maximize value for all stockholders, the Company must cease operations immediately, liquidate the Company’s assets and distribute all remaining capital to the Company’s stockholders.

Since the Company continues to operate as of the date of this Proxy Statement and has not publicly announced any plan of liquidation and dissolution, we believe the Board has rejected our proposal to immediately cease all operations, liquidate the Company’s assets and distribute all remaining capital to the Company’s stockholders. In light of the foregoing, and in order to preserve and maximize the diminishing value of the Company’s assets for the benefit of all stockholders, Tang Capital has nominated Kevin C. Tang and Andrew D. Levin, M.D., Ph.D. for election to the Board at the Annual Meeting and proposed a stockholder resolution to be voted on at the Annual Meeting whereby the stockholders will request that the Company cease operations immediately, liquidate the Company’s assets and distribute all remaining capital to the Company’s stockholders.

On February 13, 2009, Tang Capital delivered a letter (the “Letter”) to the Nominating and Governance Committee of the Company recommending Mr. Tang and Dr. Levin as nominees for election to the Board at the Annual Meeting. On the same date, Tang Capital also delivered a notice (the “Notice”) to the Company of its intention to, among other things, nominate Mr. Tang and Dr. Levin for election to the Board and propose the stockholder resolution described herein.

Since delivery of the Letter and Notice, the Board has failed to engage with Tang Capital in a dialogue on the merits of its recommendations. Tang Capital therefore decided to embark on this solicitation of proxies to elect the Nominees and approve the resolution described herein. See the information under the heading “Proposal 1 - Election of Directors” beginning on page • for additional information about the Nominees. Further, Tang Capital believes that the proposed resolution is the best way for the stockholders to let the Board know what the stockholders consider to be the best direction for the future of the Company in a manner that is quantitative, clear and indisputable.

http://seekingalpha.com/article/130370-tang-capital-partners-proxy-statement-for-vanda-pharmaceuticals-calls-for-liquidation?source=yahoo

[creppie]

Is this a good stock?

[surf1944]

UPDATE 1-Vanda gets FDA nod for schizophrenia drug
Wed May 6, 2009 6:14pm EDT
Market News

should help the whole sector on Thursday

* FDA approves schizophrenia drug

* Label to include boxed warning

* Shares jump 8 fold in after-hours trade

May 6 (Reuters) - Embattled drug-maker Vanda Pharmaceuticals Inc (VNDA.O) said U.S. health regulators approved its treatment for schizophrenia, triggering an eight-fold rise in its shares.

The U.S. Food and Drug Administration said label for the drug Fanapta, or iloperidone, will include a boxed warning, just like other atypical antipsychotic class of drugs.

The FDA said the warning will advise doctors and patients about increased risk of death, if the drug is used off-label for behavioral problems in older people with dementia-related psychosis.

The FDA had issued a not-approvable letter in October over concerns of efficacy of the atypical antipsychotic drug in comparison with Johnson & Johnson's (JNJ.N) risperidone in patients suffering from schizophrenia.

Shares of the Rockville, Maryland-based company surged to to $8.00, after the bell. They closed at $1.08 Wednesday, on Nasdaq. (Reporting by Vidya L Nathan in Bangalore; Editing by Anil D'Silva)

[mkinhaw]

Nuts a/h s
MK

[mlkrborn]

$0.85 STILL ABOVE $0.72 52 WEEKS LOW LEVEL...

[mlkrborn]

0.88 vs 0.75 on oct 16..

[surf1944]

Vanda shares rise on plans for FDA response
Thursday September 11, 7:08 pm ET
Vanda Pharma rises as company plans response to FDA rejection letter on schizophrenia drug

NEW YORK (AP) -- Shares of Vanda Pharmaceuticals Inc. ticked higher Thursday after the company said it plans to send the Food and Drug Administration a response to the rejection of its experimental schizophrenia drug iloperidone.

The stock gained 4 cents, or 3.9 percent, to end at $1.07. Shares have traded between 76 cents and $19.40 over the last 52 weeks, and are off 84 percent since January.

Shares lost most of their value in July after the FDA rejected the drug candidate, saying it was similar to drugs already on the market, including Pfizer Inc.'s ziprasidone. The agency recommended Vanda conduct additional studies that compared the drug candidate with current treatments such as Johnson & Johnson's Risperdal or Eli Lilly & Co.'s Zyprexa, instead of with just placebo. Also, additional safety data would be needed to consider another application.

Vanda said it met with the FDA on Wednesday to discuss the rejection and has agreed to send the agency a complete response in order to address concerns over the drug candidate.

[florida135]

Maybe we're getting a "buying opportunity" here.Time will tell. Florida

[AnthonyBP]

Woa what happened to this stock?

[surf1944]

I just bought some CEGE myself, most small biotech stocks are down today. Most of the traders and new money are in the banking sector today, so there is weakness in sectors that had been stronger in the past couple of months.

surf

[florida135]

Surf, because it dropped so low, instead of selling CEGE, I bought more at 0.68.Hopefully it will have some kind of rebound pretty soon. Florida

[Greencake]

CMF 20 going positive on the 6 month daily.....

"pinching" and now looking for the DI+-cross....(also watch the Fast Sto cross)

MACD 12 remains bullish....

Huge gap up to fill.....

[florida135]

Thanks Surf. Maybe CEGE has bottomed out here, so I might hang on to the shares I have a little longer. I have to decide whether to buy Vanda or Telk next week, as I want top ick up enough shares to make it worthwhile.I'm leaning alittle more to Vanda, because it seems to have held pretty nicely even though somebody dumped around 1 million shares early last week.Telk looks like it's at the bottom too. The only thing that concerns me with Telk, is the low daily volume in the stock. It would seem they would have to release some good news to get the volume up and the stock to really move. But then again, this is all guessing on my part, as things can change very quickly on Wall Street. Thanks again Surf, regards, Florida

[florida135]

At what price would you consider getting back in Surf? It seems to have support at these levels. As for CEGE, it scares me a little, so I sold some shares but still have a few more, which I was contemplating selling on even a mini rally which never came. I'm also keeping 2 other stocks on my radar, TELK, and ITUI.They both look like they have some possibilities.If you're familiar with them,please feel free to comment. Regards, Florida

[surf1944]

I sold the VNDA spike to $1.35 about a month ago, still watching it for a new entry point. The shorts are still in it pretty heavy, it just seems the overall market has been taking it down. I see your also looking at CEGE, I am also about to buy back into CEGE in the coming week.

surf





surf's up......crikey

[florida135]

Hi Surf. Reading your post I guess you're out of this one at this time. I've been watching it for a while and can't seem to figure out which way it wants to go. Some days it looks like it's going to run up, and other days some big seller comes in and knocks it down, only to have it come back to the $1.00 to the $1.05 range again. It seems to have a very tiny float, yet it's been picking up in volume in the past week or so. Since you know this stock a whole lot better than I do, I would appreciate your opinion on its possibilities. Thanks, Florida

[02opida]

Looks

like a good one to get into for long Term :)

[Gerrytheoptimist]

Hi Surf
Judging by market reaction today, most are not too excited by the conference call.
This thing may need some good news down the track for me to exit in the green.
Looks like it could be in my portfolio for the coming months....

Good luck

Gerard

[surf1944]

Vanda Pharmaceuticals Reports Second Quarter 2008 Results
Tuesday August 5, 6:30 am ET

ROCKVILLE, Md., Aug. 5 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA - News), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the second quarter ended June 30, 2008.

Vanda reported research and development (R&D) expenses in the second quarter of 2008 of $5.5 million, compared to first quarter of 2008 R&D expenses of $11.1 million and second quarter of 2007 R&D expenses of $10.2 million. The decrease in R&D expenses in the second quarter of 2008 relative to the first quarter of 2008 is primarily attributable to lower costs in the Phase III tasimelteon (VEC-162) chronic primary insomnia clinical trial for which Vanda announced top-line results in June of 2008. The decrease in R&D expenses in the second quarter of 2008 relative to the second quarter of 2007 is attributable to lower clinical trial costs in 2008 compared to costs from trials performed in 2007.

Net loss was $13.5 million for the second quarter of 2008, compared to $19.2 million in the first quarter of 2008 and $16.0 million in the second quarter of 2007. Net loss per common share for the second quarter of 2008 was $0.51, compared to $0.72 in the first quarter of 2008, and $0.60 in the second quarter of 2007.

As of June 30, 2008, Vanda's cash, cash equivalents, and marketable securities totaled approximately $65.6 million. As of June 30, 2008, the company had a total of approximately 26.6 million shares of common stock outstanding.

OPERATIONAL HIGHLIGHTS

iloperidone

On July 28, 2008, Vanda announced the receipt of a not approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application for iloperidone, an investigational atypical antipsychotic that was reviewed for the treatment of schizophrenia.

Vanda has put on hold all iloperidone-related activities pending further review.

Tasimelteon (VEC-162)

On June 26, 2008, Vanda reported positive top-line results for its tasimelteon Phase III chronic primary insomnia clinical trial. This Phase III, multi-center, placebo-controlled, 4-week trial evaluated 322 patients with chronic primary insomnia.

FINANCIAL DETAILS

-- Operating Expenses. Second quarter 2008 R&D expenses, primarily consisting of salaries and related costs of R&D personnel, stock-based compensation, and the costs of consultants, materials and supplies associated with clinical trials and research initiatives, were $5.5 million, down from $11.1 million in the previous quarter and down from $10.2 million in the second quarter of 2007. The decrease in R&D expenses in the second quarter of 2008 relative to the first quarter of 2008 is primarily attributable to lower costs in the Phase III tasimelteon chronic primary insomnia clinical trial for which Vanda reported the top-line results in June of 2008. The decrease in R&D expenses in the second quarter of 2008 relative to the second quarter of 2007 is primarily attributable to lower clinical trial costs in the second quarter of 2008 versus the costs from trials conducted in the second quarter of 2007.

General and administrative (G&A) expenses totaled $8.5 million in the second quarter of 2008, down from $9.0 million in the first quarter of 2008, and up from $7.4 million in the second quarter of 2007. The decrease in G&A expenses in the second quarter of 2008 relative to the first quarter of 2008 is primarily due to lower employee stock-based compensation expense. The increase in G&A expenses in the second quarter of 2008 relative to the second quarter of 2007 is primarily due to increased pre-launch commercial activities for iloperidone.

Employee stock-based compensation expense recorded in the second quarter of 2008 was $4.0 million. Of the total $4.0 million of non-cash charges, $0.7 million was recorded in R&D expenses and $3.3 million was recorded in G&A expenses. For both the first quarter of 2008 and the second quarter of 2007, total stock-based compensation was $5.1 million. The decrease in stock-based compensation from the second quarter of 2008 compared to the first quarter of 2008 and the second quarter of 2007 is primarily due to the lower fair market value of options granted in 2008.

-- Net loss for the second quarter of 2008 was $13.5 million. This compares to a net loss of $19.2 million in the first quarter of 2008, and $16.0 million in the second quarter of 2007.

-- Net loss per common share for the second quarter of 2008 was $0.51 compared to $0.72 in the first quarter of 2008 and $0.60 in the second quarter of 2007.

-- Cash and marketable securities decreased by $11.4 million during the second quarter of 2008. Changes included $13.5 million of net losses and decreases in accrued R&D expenses and accounts payable of $0.9 million, net increases in prepaid expenses of $0.9 million, fixed asset purchases of $0.3 million offset by $4.1 million in non-cash depreciation, amortization, and stock-based compensation expenses and net decreases in other working capital of $0.1 million.

-- Vanda's cash, cash equivalents, and marketable securities at the end of the second quarter of 2008 totaled approximately $65.6 million, compared to approximately $93.2 million as of December 31, 2007.

FINANCIAL GUIDANCE

The company has placed on hold all iloperidone-related activities and is undertaking steps to minimize its cash burn. The company is also evaluating all options for its development pipeline and will provide guidance as soon as its plans are more definitive.

CONFERENCE CALL

The company has scheduled a conference call for today, Tuesday, August 5, 2008 at 10:30 AM ET. During the call, Mihael H. Polymeropoulos, M.D., President and CEO, and Steven A. Shallcross, Sr. Vice President and CFO, will discuss quarterly results and other corporate activities. Investors can call 1-800-259-0251 (domestic) and 1-617-614-3671 (international) prior to the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos. A replay of the call will be available Tuesday, August 5, 2008, at 12:30 PM ET and will be accessible until Tuesday, August 12, 2008, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 98529573.

The conference call will be broadcast simultaneously on the company's Web site, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the Web site at least 15 minutes early to register, download, and install any necessary software. The call will also be archived on the Vanda Web site for a period of 30 days, through September 4, 2008.

[Gerrytheoptimist]

I am up for a few more shares around the $1 mark, average down and see what the numbers look like Tuesday, order is in.
If they are good I may be able to exit on the pop.
If they are poor I get the opportunity to become a longer term share holder.
Showing on bottom bouncer at blue horse shoe saloon, not sure how heavily that is followed but they do get some good picks.

Good luck

Gerard

[apocalypsenow73]

Is that the reason for that volume ? someone knows something?

[surf1944]

Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
Thursday July 31, 1:46 pm ET
Conference Call and Webcast to Follow

ROCKVILLE, Md., July 31 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA - News), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced it will release results for the second quarter ended June 30, 2008, on Tuesday, August 5, 2008, before the market opens. A full text copy of the release will be disseminated at that time.
Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results and other corporate developments at 10:30 AM ET on Tuesday, August 5, 2008. Also participating on the call will be Steven A. Shallcross, Senior Vice President and CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.


The teleconference dial-in numbers are as follows:
Domestic callers 1-800-259-0251
International callers 1-617-614-3671

The conference call will be broadcast simultaneously and archived on the company's Web site, www.vandapharma.com . Investors should go to the Web site at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Tuesday, August 5, 2008, beginning at 12:30 PM ET and will be accessible until Thursday, September 4, 2008, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 98529573.

[surf1944]

I'll be using this rally to clear out what I bought this week after the FDA rejection. The most I see VNDA going up is the gap area just under $1.50, if it goes past that something else is going on and not just short covering.

GLTA





surf's up......crikey